Rottapharm Biotech S.R.L.
Records under this name other than the patents Rottapharm Biotech S.R.L. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 9 patents it holds.
Back to Rottapharm Biotech S.R.L.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,994,181 | 6-1H-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents Term ended Term ended Aug 3, 2026 · USPTO record | Term ended | Term ended Aug 3, 2026 | USPTO record |
| US 8,193,353 | 6-1H-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents Term ended Term ended Aug 3, 2026 · USPTO record | Term ended | Term ended Aug 3, 2026 | USPTO record |
| US 8,633,208 | 6-1H-imidazo-quinazoline and quinolines derivatives, new MAO inhibitors and imidazoline receptor ligands Lapsed on the fee record Ended Jan 21, 2026 · USPTO record | Lapsed on the fee record | Ended Jan 21, 2026 | USPTO record |
| US 9,120,824 | Cyclic amine derivatives as EP4 receptor agonists Lapsed on the fee record Ended Sep 1, 2023 · USPTO record | Lapsed on the fee record | Ended Sep 1, 2023 | USPTO record |
| US 7,968,558 | Amidine derivatives of 2-heteroaryl-quinazolines and quinolines; potent analgesics and anti-inflammatory agents Lapsed on the fee record Ended Jun 28, 2023 · USPTO record | Lapsed on the fee record | Ended Jun 28, 2023 | USPTO record |
| US 9,062,033 | Chemical compounds Lapsed on the fee record Ended Jun 23, 2023 · USPTO record | Lapsed on the fee record | Ended Jun 23, 2023 | USPTO record |
| US 8,859,608 | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction Lapsed on the fee record Ended Oct 14, 2022 · USPTO record | Lapsed on the fee record | Ended Oct 14, 2022 | USPTO record |
| US 8,828,987 | Pyridine amide derivatives as EP4 receptor antagonists Lapsed on the fee record Ended Sep 9, 2022 · USPTO record | Lapsed on the fee record | Ended Sep 9, 2022 | USPTO record |
| US 7,674,809 | Anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production Lapsed on the fee record Ended Mar 9, 2022 · USPTO record | Lapsed on the fee record | Ended Mar 9, 2022 | USPTO record |
| US 9,631,029 | Anti-ADAMTS-5 antibody, derivatives and uses thereof Lapsed on the fee record Ended Apr 25, 2021 · USPTO record | Lapsed on the fee record | Ended Apr 25, 2021 | USPTO record |